Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 4 Issue 11

Early Switch from Intravenous to Oral Therapy in Hospitalized Patients in Neuroscience Center at KFMC: A Cost-minimization Approach

Leena H. Saeed1*, Nahed Y Lubbad2**, Esraa A Mahmoud 3, Bennette M Alejandro4

1*Principle Investigator: Clinical pharmacist, Neurology, King Fahad Medical city, Riyadh, KSA
2**Co-Investigator: Clinical pharmacist, Neurology, King Fahad Medical City, Riyadh, KSA
3MD, Alfaisal University, Riyadh, KSA
4Pharmacist assistant, King Fahad Medical City, Riyadh, KSA

*Corresponding Author: Leena H Saeed, Clinical pharmacist, Neurology, King Fahad Medical city, Riyadh, KSA.

Received: September 14, 2020; Published: October 12, 2020



  Most of the hospital admitted patients with severe diseases are usually started on intravenous (IV) medications, in particular, those who are released from operation room to intensive care units. Although IV to oral therapy conversion is not suitable for critical patients or those who are unable to absorb orally, there is still a good number of patients in each hospital, who are candidates for the switchover from IV to oral therapy.

Keywords: IV to Oral, Pharamcoeconomic, Switch, Hospitalized



  1. World Health Day. Antibiotic resistance: No action today, no cure tomorrow (2011).
  2. The British Thoracic Society and Public Health Laboratory Service. “Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome”. Quarterly Journal of Medicine 239 (1987): 195-220.
  3. Solomkin JS., et al. “Results of a Randomized Trial Comparing Sequential lntravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to lmipenem/Cilastatin for Intra-Abdominal Infections”. Annuals of Surgery3 (1996): 303-315.
  4. Weingarten SR., et al. “Identification of low-risk hospitalized patients with pneumonia for early conversion to oral antimicrobial therapy”. Chest 105 (1994): 1109-1115.
  5. Palanisamy A., et al. “Conversion of intravenous to oral antimicrobial therapy in South Indian population”. International Journal of Research in Pharmaceutical and Biomedical Sciences 2 (2011): 1258-1260.
  6. Lee SL., et al. “Clinicians’ knowledge, beliefs and acceptance of intravenous to oral antibiotic switching, Hospital Pulau Pinang”. Medical Journal of Malaysia 67 (2012): 190.
  7. Product Information: ZANTAC (R) oral tablets, effervescent oral tablets, oral syrup, ranitidine hcl oral tablets, effervescent oral tablets, oral syrup. GlaxoSmithKline, Research Triangle Park, NC (2008).
  8. Chau NP., et al. “Ranitidine kinetics in normal subjects”. Clinical Pharmacology and Therapeutics 31 (1982): 770-774.
  9. McNeil JJ., et al. “Pharmacokinetics of the H2-receptor antagonist ranitidine in man”. British Journal of Clinical Pharmacology 12 (1981): 411-415.
  10. Duggan DE., et al. “Bioavailability of oral dexamethasone”. Clinical Pharmacology and Therapeutics 18 (1975): 205-209.
  11. Wilson EA and Brodie MJ. “New antiepileptic drugs”. Bailliere's Clinical Neurology 4 (1996): 723-747.
  12. Walker MC and Patsalos PN. “Clinical pharmacokinetics of new antiepileptic drugs”. Pharmacology Therapy 3 (1995): 351-384.
  13. Patsalos PN., et al. “The pharmacokinetics of levetiracetam (ucb L059) in patients with intractable epilepsy (abstract 2.72)”. Epilepsia 36 (1995): 52.
  14. Regardh CG. “Pharmacokinetics and metabolism of omeprazole in man”. Scandinavian Journal of Gastroenterology 21 (1986): 99-104.
  15. Andersson T. “Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole”. Clinical Pharmacokinetics 31 (1996): 9-28.
  16. Product Information: PROTONIX (R) delayed-release oral tablets, suspension, pantoprazole sodium delayed-release oral tablets, suspension. Wyeth Pharmaceuticals, Inc, Philadelphia, PA, 2008.
  17. Pue MA., et al. “Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects”. European Journal of Clinical Pharmacology 44 (1993): 575-578.
  18. Derendorf H., et al. “Pharmacokinetics and oral bioavailability of hydrocortisone”. Journal of Clinical Pharmacology 31 (1991): 473-476.
  19. Thakker KM. “Predicting the dose-dependent bioavailability of hydrocortisone and chlorothiazide in humans (letter)”. Journal of Pharmaceutical Sciences 72 (1983): 577.
  20. Teich JM., et al. “An information system to promote intravenous-to-oral medication conversion”. Proceedings of the AMIA Symposium (1999): 415-419.
  21. Ehrenkranz NJ., et al. “Intervention to discontinue parenteral antimicrobial therapy in hospitalized patients with urinary tract infection, skin and soft tissue infection, or no evident infection”. Infection Control and Hospital Epidemiology 9 (1993): 517-522.
  22. Stirling AL., et al. “Experience with a decentralized IV to PO ofloxacin conversion program”. Formulary (1999): 34688-34703.


Citation: Leena H Saeed., et al. “Early Switch from Intravenous to Oral Therapy in Hospitalized Patients in Neuroscience Center at KFMC: A Cost-minimization Approach". Acta Scientific Medical Sciences 4.11 (2020): 21-26.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US